FINAL HOURS: Lock in your InvestingPro subscription for 50% off before sale ends
NutriBand Inc. (NASDAQ:NTRB), a Nevada-based pharmaceutical company with a market capitalization of approximately $78 million, has announced the expected issuance of a U.S. patent for its Aversa™ abuse deterrent technology. The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the patent application titled "Abuse and Misuse Deterrent Transdermal Systems" on February 3, 2025. The company’s stock has shown remarkable strength, delivering a 168% return over the past year, according to InvestingPro data.
The Notice of Allowance is a significant milestone for NutriBand, indicating that the USPTO intends to grant a patent once administrative procedures are completed. The technology covered by the application includes a transdermal system designed to deter the abuse and misuse of active substances.
NutriBand’s core focus lies in the development of transdermal pharmaceutical products. The company’s proprietary technology, Aversa™, aims to address the ongoing issue of prescription drug abuse by incorporating abuse deterrent features into transdermal systems, which deliver medication through the skin. While the company maintains a strong financial position with a current ratio of nearly 5x and operates with minimal debt, InvestingPro data shows it is not yet profitable, with an EBITDA of -$5.75 million in the last twelve months.
The forthcoming patent represents a key development for NutriBand, potentially strengthening its intellectual property portfolio and enhancing its position within the orthopedic, prosthetic, and surgical appliances and supplies sector.
NutriBand, previously known as Nutriband Inc. until a name change on June 1, 2016, operates out of its headquarters in Orlando, Florida. The company is listed on The Nasdaq Stock Market LLC under the ticker symbols NTRB for its common stock and NTRBW for its warrants.
This announcement, made initially on February 7, 2025, is based on a press release statement and forms part of a Current Report on Form 8-K filed with the SEC on February 12, 2025. The information is provided in compliance with Regulation FD (Fair Disclosure) and includes financial statements and exhibits as part of the filing.
Investors and stakeholders in the pharmaceutical and healthcare sectors may view this patent allowance as a positive development for NutriBand, reflecting the company’s ongoing commitment to innovation and the protection of its technological advancements. InvestingPro subscribers can access 8 additional key insights about NutriBand, including detailed financial health metrics and growth forecasts, to make more informed investment decisions.
In other recent news, Nutriband Inc., a developer of transdermal pharmaceutical products, has secured a Notice of Allowance from the United States Patent and Trademark Office for its AVERSA™ abuse deterrent technology. The forthcoming patent is set to strengthen Nutriband’s intellectual property rights in the U.S. for its portfolio of abuse deterrent transdermal products. Nutriband’s leading product in development, AVERSA™ Fentanyl, is on track to potentially become the first abuse deterrent pain patch in the market.
In other recent developments, Nutriband shareholders approved several key proposals at their Annual Meeting, including the election of directors and approval of the company’s amended stock option plan. All seven director nominees were elected to serve one-year terms on the company’s board. The company’s 2024 Amended and Restated Stock Option Plan was also approved, aiming to incentivize and retain executives and employees through equity compensation.
Noble Capital has initiated coverage on Nutriband with an Outperform rating and a price target of $13.00. The analysts are optimistic about Nutriband’s future, particularly regarding its upcoming Phase 1 clinical trial. The firm’s analysis is based on Nutriband’s projected earnings per share (EPS) of $1.45 for the fiscal year 2027, discounted at a rate of 30% per year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.